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ABSTRACT  
The cytotoxic potency of a series of triphenyltin(IV) compounds of general composition [Ph3Sn(Ln)] (1-6) 
has been probed in vitro employing MDAMB-231 (human breast cancer) and HeLa (human cervical 
cancer) cell lines, where  Ln = L1-3; isomeric 2/3/4-{(E)-2-[4-(dimethylamino)phenyl]diazenyl}benzoates  
and L4-6 are their corresponding isoelectronic imino analogues 2/3/4-[(E)-{[4-
(dimethylamino)phenyl]methylidene}amino]benzoates. Compounds 1-6 have been characterized by 
elemental analysis and their spectroscopic properties were studied using IR and NMR (1H, 13C, 119Sn) 
techniques. The molecular structures of a pro-ligand 2-[(E)-{[4-
(dimethylamino)phenyl]methylidene}amino]benzoic acid (HL4) and two representative molecules, 
Ph3Sn(L2) 2 and Ph3Sn(L5) 5, have been determined by X-ray crystallography. Structural analyses of 2 and 
5 revealed distorted tetrahedral geometries within C3O donor sets owing to monodentate modes of 
coordination of the respective carboxylate ligands, close intramolecular Sn…O(carbonyl) interactions 
notwithstanding.  Cytotoxic studies in vitro in MDAMB-231 and HeLa cell lines revealed high activity, in 
sub-micromolar range, for all investigated compounds. Among these, 1 and 3 exhibited potent cytotoxicity 
most effectively towards MDAMB-231 cells with a IC50 value of 1.19 and 1.44 µM, respectively, whereas 
5 showed remarkable activity towards HeLa cells with a IC50 value of 0.88 µM, yet the series of 
compounds had minimal cytotoxic effect on normal HEK 293 (human embryonic kidney) cell line. The 
underlying investigation suggested that the compounds exert potent antitumor effect by elevating 
intracellular reactive oxygen species generation and cause delay in cell cycle by inhibiting cells at G2/M 
phase. The results presented herein suggest further development of this class of triphenyltin(IV) 
compounds-based drugs as potential anti-cancer therapies should be pursued. 
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1. Introduction 
Cisplatin, cis-diammine-dichloroplatinum(II) (CDDP), a square planar Pt(II) complex remains in 
the frontline of inorganic chemotherapeutic agents for the treatment for cancer [1-4]. The clinical 
effectiveness of CDDP is limited by considerable side effects and the emergence of drug resistance. 
Consequently, a number of second- and third-generation CDDP analogues including carboplatin, 
oxaliplatin, nedaplatin, heptaplatin, lobaplatin and satraplatin were developed for use in the treatment of 
various cancers. These advances have spurred a surge of investigations to identify new inorganic agents 
(non-platinum metals) for use in chemotherapy with improved specificity and decreased toxic side effects. 
Accordingly, non-platinum metallodrugs such as Ru, Cu, Au, Pd, Fe, Co, Ti, Ga, Ni, Rh, Ir, Sn, Os, Zn, V, 
Ag, Re, Mo and lanthanide complexes have emerged and shown to exhibit comparable or better cytotoxic 
properties accompanied by different specificities towards cancer cells, and by a more favourable 
pharmacological and toxicological profiles [5,6]. Review articles describing the application of transition 
metal complexes as anti-cancer agents are available in the literatures [7-23].  
On the other hand, organotin(IV) compounds have displayed diverse medicinal applications such 
as anti-viral, anti-microbial, anti-parasitic, anti-hypertensive, anti-hyperbilirubinemia and anti-cancer 
activities, apart from their standard uses as biocides, catalyzers and stabilizers [24-29]. Compared to 
standard drugs, the majority of organotin(IV) carboxylates discussed in the literature have shown superior 
anticancer activity against various cell lines. Additionally, some of them have demonstrated distinct 
anticancer activity even against CDDP-resistive cancer cells. Organotin(IV) compounds with pronounced 
medicinal properties also exhibit drawbacks such as reproductive toxicity, neurotoxicity and other toxic 
effects apart from poor water solubility; however, these can be circumvented by a rational design of the 
structures of the compounds but the vital point still remains the activity. In practice, organotin(IV) 
compounds are dissolved in DMSO and diluted with test medium prior to in vitro testing. Nevertheless, the 
limited solubility needs to be further enhanced in a way comparable to CDDP, which also shows limited 
water solubility. It is therefore important to find more effective and safer organotin(IV) compounds for 
therapeutic use by designing and synthesizing new compounds and to find suitable means of their delivery 
to the bio-targets. In this pursuit, recently a novel biocompatible strategy of drug delivery employing 
nanostructured silica-based material loaded with triphenyltin(IV) compound was used. This resulted in 
increase in efficacy of the drug and the pattern of action leads to the non-aggressive suppression of 
melanoma tumor growth with non-recognizable toxicity toward normal tissue [30]. While the potency of a 
drug is a very important consideration, drug selectivity towards cancer cells is key to ensuring both safety 
and effectiveness [31]. Additionally, the mechanism of action of organotin(IV) compounds in achieving 
cell death remains uncertain, and hence additional work is essential to identify the actual apoptotic or 
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necrotic pathways. 
In view of the above, careful functionalization of a series of organotin compounds was 
undertaken. In this endeavour, six pro-ligands (i) isomeric 2-, 3- and 4-{(E)-2-[4-
(dimethylamino)phenyl]diazenyl}benzoic acids and their isoelectronic imino counterparts, i.e. (ii) 2-, 3- 
and 4-[(E)-{[4-(dimethylamino)phenyl]methylidene}amino]benzoic acid, have been designed and their 
triphenyltin(IV) esters prepared (Fig. 1). In the first three pro-ligands (HL1-3), the aryl moieties are linked 
by a diazenyl skeleton while in the others (HL4-6) by an imino group, substitution patterns which offer 
flexibility in the molecules. The presence of the carboxylate group is vital for aqueous solubility and results 
in increased cellular accumulation [32,33]. The incorporation of the triphenyltin(IV) moiety in the molecule 
offers much higher activities when compared with titanocene derivatives and CDDP [34-36]. Thus, it is 
expected that the modification of the carboxylate ligands in the current series by incorporating SnPh3 can 
optimize the cytotoxicity [37,38] while varying the location of the triphenyltin ester can modulate the 
activity at a specific target. In this context, cytotoxic properties of series of [Ph3Sn(Ln)] complexes [Ln =  
L1-3 (1-3) and L4-6 (4-6)], were determined towards the MDAMB-231 (human breast cancer) and HeLa 
(human cervical cancer) cell lines. To realize the mechanistic/mode of cell death objective, an additional 
series of experiments were conducted: (i) the cytotoxic activity was examined by MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (ii) the ability of the test compounds to 
generate ROS (reactive oxygen species) in the cells was examined using DCFH-DA (dichlorodihydro-
fluorescein diacetate) dye (iii) apoptosis or mode of cell death was detected by Hoechst 33342/PI 
(propidium iodide) and annexin V-PI assay and (iv) cell cycle arrest by the compounds were examined by 
FACS (fluorescence-activated cell sorting) studies. The biological results indicated that the triphenyltin(IV) 
compounds show potent cytotoxicity which can be modulated either by varying the positions of the 
triphenyltin(IV) ester across a series or switching from triphenyltin(IV)- diazobenzoato- to -iminobenzoato- 
ligands. The present studies demonstrated that the triphenyltin(IV) compounds exert their cytotoxic effect 
by elevating intracellular ROS generation as discussed below. 
 
Insert Fig. 1. 
 
2. Experimental 
2.1. Materials and physical measurements  
Ph3SnOH (Aldrich), anthranilic acid (Sigma-Aldrich), 3-aminobenzoic acid, 4-aminobenzoic 
acid, 4-(dimethylamino)benzaldehyde (SRL) and dimethylaniline (sd fine-chem) were used without further 
purification. The solvents used in the reactions were of AR grade and were dried using standard 
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procedures. Toluene was distilled from sodium. Dulbecco’s modified eagle medium (DMEM), fetal bovine 
serum (FBS) (Cellclone, Genetix Biotech Asia), penicillin 1000 IU, streptomycin 10 mg/mL, trypsin, 3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide dye (MTT) (Himedia), dimethyl sulphoxide 
(DMSO), RNAse (GeNie, Merck), 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA), Hoechst 33342 
(Sigma), propidium iodide (PI) (EMD Millipore-Calbiochem), Annexin V Alexa flour 488 conjugate (Life 
Technologies; Invitrogen Bioservices India Pvt. Ltd.), cytoplatin (Cipla; generic name- cisplatin), Triton X-
100 and other analytical grade chemicals (Lobachemie) were used. 
Melting points were measured using a Büchi melting point apparatus M-560 and are uncorrected. 
Carbon, hydrogen and nitrogen analyses were performed with a Perkin-Elmer 2400 series II instrument. IR 
spectra in the range 4000-400 cm-1 were obtained on a Perkin Elmer Spectrum BX series FT-IR 
spectrophotometer with samples investigated as KBr discs. Absorption measurements of compounds 1-6 
were carried out on a Perkin-Elmer Lambda25 spectrophotometer at ambient temperature in benzene and 
DMSO solutions. 1H and 13C{1H} NMR spectra, measured at 400.13 and 100.62 MHz respectively, were 
recorded on a Bruker AMX 400 spectrometer. 119Sn NMR spectra were measured on a Jeol GX 270 
spectrometer at 100.75 MHz. The 1H, 13C and 119Sn chemical shifts were referenced to Me4Si (δ 0.00 ppm), 
CDCl3 (δ 77.00 ppm), and Me4Sn (δ 0.00 ppm), respectively. Equipment such as ELISA plate reader, 
Microscan (MS5608A), inverted fluorescence microscopy (Nikkon E800) and Inverted fluorescent 
microscope (Evos FL, Life technologies, AMF4300) were used for biological work. 
 
2.2. Synthesis of pro-ligands 
Pro-ligands 2-{(E)-2-[4-(dimethylamino)phenyl]diazenyl}benzoic acid (HL1), 3-{(E)-2-[4-
(dimethylamino)phenyl]diazenyl}benzoic acid (HL2) and 4-{(E)-2-[4-(dimethylamino)phenyl]-
diazenyl}benzoic acid (HL3) and 2-[(E)-{[4-(dimethylamino)phenyl]methylidene}amino]benzoic acid 
(HL4) were prepared by the method described earlier [39] and purities were established from melting point, 
elemental analysis and 1H NMR spectroscopy prior to use. The synthetic details of the pro-ligands HL5 and 
HL6, including their characterization and spectroscopic data are described below.  
 
 
2.2.1. Synthesis of 3-[(E)-{[4-(dimethylamino)phenyl]methylidene}amino]benzoic acid (HL5) 
 A similar synthetic procedure to that used for HL4 was used [39] except that anthranilic acid was 
replaced by 3-aminobenzoic acid. The crude product was then recrystallized from methanol to give brown 
powder in 65% yield. M.p.: 200-202 °C. Anal. calc. for C16H16N2O2: C, 71.62; H, 6.01; N, 10.44 %. Found. 
C, 71.60; H, 5.80; N, 10.28 %. IR (cm-1): 1682 ν(OCO)asym. 1H-NMR (CDCl3 + DMSO-d6): δH; 8.04 [s, 1H, 
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H-15], 7.50-7.30 [m, 2H, H-2 & H-4], 7.15-7.0 [m, 1H, H-5], 7.13-7.04 [m, 1H, H-5], 6.98-6.75 [m, 2H, H-
9 & H-13], 6.50 [d, 1H, H-6], 6.45-6.35 [m, 2H, H-10 & H-12], 2.85-2.60 [s, 6H, H-14] ppm. Signals for 
the carboxylic acid were exchanged due to presence of water in the solvent. 13C-NMR (CDCl3 + DMSO-
d6): δC; 189.5 [C-1], 160.5 [C-15], 152.3 [C-11], 148.5 [C-7], 131.7 [C-3], 130.4 [C-9 & C-13], 129.0 [C-
5], 121.3 [C-8], 118.0 [C-6], 114.6 [C-4], 111.2 [C-10 & C-12], 110.8 [C-2], 39.6 [C-14] ppm.  
 
2.2.2. Synthesis of 4-[(E)-{[4-(dimethylamino)phenyl]methylidene}amino]benzoic acid (HL6)  
 A similar synthetic procedure to that used for HL4 was used [39] except that anthranilic acid was 
replaced by 4-aminobenzoic acid. The crude product was then recrystallized from methanol to give a 
golden yellow powder in 66% yield. M. p.: 270-272 °C. Anal. calc. for C16H16N2O2: C, 71.62; H, 6.01; N, 
10.44 %. Found. C, 71.72; H, 6.20; N, 10.58 %. IR (cm-1): 1680 ν(OCO)asym. 1H-NMR (CDCl3 + DMSO-
d6): δH; 9.74 [s, 1H, H-15], 7.83 [d, 2H, H-3 & H-5], 7.75 [d, 2H, H-9 & H-13], 6.74 [d, 2H, H-2 & H-6], 
6.67 [d, 2H, H-10 & H-12], 3.13 [s, 6H, H-14] ppm. Signals for the carboxylic acid were exchanged due to 
presence of water in the solvent. 13C-NMR (CDCl3 + DMSO-d6): δC; 189.7 [C-1], 168.3 [C-15], 154.0 [C-
7], 153.0 [C-11], 131.2 [C-3 & C-5], 124.4 [C-4], 120.7 [C-9], 117.0 [C-13], 112.6 [C-2 & C-6], 110.8 [C-
1- & C-12], 39.5 [C-14] ppm.   
 
2.3. Synthesis and characterization of triphenyltin(IV) compounds  
A general method was followed for the synthesis of compounds 1-6. In a typical procedure, a 
mixture of Ph3SnOH and the appropriate pro-ligands HLn (n = 1-6) in a 1:1 stoichiometric ratio was heated 
to reflux in anhydrous toluene (50 mL) for 8 h in a round bottom flask equipped with a Dean-Stark 
apparatus and a water-cooled condenser. The reaction mixture was filtered while hot and the solvent was 
removed using a rotary evaporator. The residue was washed, boiled with hexane, filtered and dried in 
vacuo. The residue upon crystallization using appropriate solvent(s) yielded the desired product. The 
specific details pertaining to reactants, analytical and characterization data for the complexes are given 
below. 
 
2.3.1. Ph3SnL1 (1) 
  The synthesis of 1 has been reported earlier [40] by two different methods, utilizing reactions of 
Ph2SnO and HL1 as well as (Ph3Sn)2O and HL1, both conducted in ethanol. The yields of the products were 
50% and 68%, respectively, and the melting point was not reported. In the present investigation, 1 was 
prepared by following a general method described above. Ph3SnOH (0.68 g, 1.85 mmol); HL1 (0.50 g, 1.85 
mmol). Recrystallized from toluene to give a red microcrystalline product in 78% yield. M.p.: 175-177 °C. 
Anal. calc. for C33H29N3O2Sn: C, 64.10; H, 4.73; N, 6.80 %. Found. C, 63.96; H, 4.70; N, 6.58 %. IR (cm-
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1): 1723 ν(OCO)asym, 1369 ν(OCO)asym. Electronic absorption data (benzene) λmax, nm; (ε [M‒1]): 430 sh 
(3,402), 478 (6,907). 1H NMR (CDCl3); δH: 7.74-7.52 [m, 8H, H-3, H-6 & H-2*], 7.44-7.11 [m, 13H, H-4, 
H-5, H-9, H-13, H-3* & H-4*], 6.52 [d, 2H, H-10 & H-12], 3.00 [s, 6H, H-14] ppm. 13C-NMR (CDCl3); 
δC: 172.6 [C-1], 152.4 [C-7], 152.1 [C-11], 145.8 [C-8], 137.9 [1J (13C-119/117Sn) = 640/620 Hz, C-1*], 
136.5 [2J (13C-119/117Sn) = 48 Hz, C-2*], 135.3 [ArC], 131.6 [ArC], 130.2 [ArC], 130.1 [ArC], 129.6 [4J 
(13C-119/117Sn) = 13 Hz, C-4*], 128.7 [ArC], 128.6 [ArC], 128.4 [3J (13C-119/117Sn) = 63 Hz, C-3*], 126.6 
[ArC], 111.0 [ArC], 39.7 [C-14] ppm. 119Sn NMR (CDCl3); δSn:  ‒109.5 ppm. 
 
2.3.2. Ph3SnL2 (2) 
 Ph3SnOH (0.68 g, 1.85 mmol); HL2 (0.50 g, 1.85 mmol). Recrystallized from toluene to give an 
orange-red microcrystalline product in 75% yield. M.p.: 162-163 °C. Anal. calc. for C33H29N3O2Sn: C, 
64.10; H, 4.73; N, 6.80 %.  Found. C, 64.26; H, 4.88; N, 6.78 %. IR (cm-1): 1615 ν(OCO)asym, 1363 
ν(OCO)asym. Electronic absorption data (benzene) λmax, nm; (ε [M‒1]): 418 (2,474).  1H NMR (CDCl3); δH: 
8.53 [s, 1H, H-2], 8.09-7.76 [m, 10H, H-4, H-6, H-9, H-13 & H-2*], 7.47-7.17 [m, 10H, H-5, H-3* & H-
4*], 6.67 [d, 2H, H-10 & H-12], 3.00 [s, 6H, H-14] ppm. 13C-NMR (DMSO-d6 + CDCl3); δC: 169.0 [C-1], 
152.3 [C-7], 152.2 [C-11], 142.8 [C-8], 142.6 [1J (13C-119/117Sn) = 630/620 Hz, C-1*], 136.1 [2J (13C-
119/117Sn) = 45 Hz, C-2*], 130.0 [ArC], 128.7 [4J (13C-119/117Sn) = 13 Hz, C-4*], 128.4 [ArC], 128.0 [3J (13C-
119/117Sn) = 65 Hz, C-3*], 124.9 [ArC], 124.6 [ArC], 122.2 [ArC], 111.1 [ArC], 40.0 [C-14] ppm. 119Sn 
NMR (CDCl3); δSn:  ‒107.3 ppm. 
 
2.3.3. Ph3SnL3 (3) 
 Ph3SnOH (0.68 g, 1.85 mmol); HL3 (0.50 g, 1.85 mmol). Recrystallized from benzene to give a 
dark-red microcrystalline product in 76% yield. M.p.: 214-216 °C. Anal. calc. for C33H29N3O2Sn: C, 64.10; 
H, 4.73; N, 6.80 %. Found. C, 64.16; H, 4.80; N, 6.70 %. IR (cm-1): 1623 ν(OCO)asym, 1364 ν(OCO)asym. 
Electronic absorption data (benzene)  λmax, nm; (ε [M‒1]): 433 (5,154). 1H NMR (CDCl3); δH: 8.16 [d, 2H, 
H-3 & H-5], 7.83-7.74 [m, 10H, H-2, H-6, H-9, H-13 & H-2*], 7.47- 7.25 [m, 9H, H-3* & H-4*], 6.66 [d, 
2H, H-10 & H-12], 3.01 [s, 6H, H-14] ppm. 13C-NMR (CDCl3); δC: 172.4 [C-1], 155.8 [C-7], 152.8 [C-11], 
143.7 [C-8], 138.4 [1J (13C-119/117Sn) = 640/625 Hz, C-1*], 136.9 [2J (13C-119/117Sn) = 48 Hz, C-2*], 130.7 
[ArC], 130.2 [4J (13C-119/117Sn) = 12 Hz, C-4*], 128.0 [3J (13C-119/117Sn) = 63 Hz, C-3*], 125.5 [ArC], 121.8 
[ArC], 111.5 [ArC], 40.3 [C-14] ppm. 119Sn NMR (CDCl3); δSn: ‒108.7 ppm.  
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2.3.4. Ph3SnL4 (4) 
 Ph3SnOH (0.68 g, 1.85 mmol); HL4 (0.50 g, 1.86 mmol). Recrystallized from benzene to give an 
orange-red powder in 76% yield. M.p.: 144-146 °C. Anal. calc. for C34H30N2O2Sn: C, 66.15; H, 4.90; N, 
4.54 %. Found. C, 66.16; H, 4.80; N, 4.70 %. IR (cm-1): 1639 ν(OCO)asym, 1367 ν(OCO)asym. Electronic 
absorption data (benzene) λmax, nm; (ε [M‒1]): 416 (7,010).  1H NMR (CDCl3); δH: 8.28 [s, 1H, H-15], 7.88 
[d, 1H, H-3], 7.80-7.40 [m, 6H, H-2*], 7.44-7.30 [m, 12H, H-4, H-9, H-13, H-3* & H-4*], 7.14 [t, 1H, H-
5], 6.85-6.50 [m, 3H, H-6, H-10 & H-12], 3.10-2.90 [s, 6H, H-14] ppm. 13C-NMR (CDCl3); δC: 191.1 [C-
1], 161.8 [C-15], 153.3 [C-7], 147.0 [C-11], 139.0 [1J (13C-119/117Sn) = 585/570 Hz, C-1*], 137.6 [2J (13C-
119/117Sn) = 47 Hz, C-2*], 131.4 [ArC], 131.3 [ArC], 130.8 [4J (13C-119/117Sn) = 13 Hz, C-4*], 129.8 [ArC], 
129.7 [ArC], 129.6 [3J (13C-119/117Sn) = 63 Hz, C-3*], 122.8 [ArC], 121.5 [ArC], 117.4 [ArC], 112.2 [ArC], 
111.6 [ArC], 40.8 and 40.7 [C-14] ppm. 119Sn NMR (CDCl3) ); δSn: ‒109.5 ppm. 
 
2.3.5. Ph3SnL5 (5)  
 Ph3SnOH (0.68 g, 1.85 mmol); HL5 (0.50 g, 1.86 mmol). Recrystallized from acetonitrile to give a 
dark-orange crystalline material in 71% yield. M.p.: 184-186 °C. Anal. calc. for C34H30N2O2Sn: C, 66.15; 
H, 4.90; N, 4.54 %.  Found. C, 65.96; H, 4.80; N, 4.60 %. IR (cm-1): 1629 ν(OCO)asym, 1332 ν(OCO)asym. 
Electronic absorption data (benzene)  λmax, nm; (ε [M‒1]): 434 (4,639). 1H-NMR (CDCl3): δH; 8.37 [s, 1H, 
H-15], 7.96 [d, 1H, H-4], 7.85-7.70 [m, 7H, H-2 & H-2*], 7.60-7.40 [m, 10H, H-5, H-3* & H4*], 7.25-7.21 
[m, 2H, H-9, H-13], 6.87 [d, 1H, H-6], 6.80-6.70 [m, 2H, H-10 & H-12], 3.09-3.07 [s, 6H, H-14] ppm. 13C-
NMR (CDCl3 + DMSO-d6): δC; 190.1 [C-1], 160.6 [C-15], 154.6 [C-11], 152.8 [C-7], 143.3 [C-9 & C-13], 
137.3 [1J (13C-119/117Sn) = 630/620 Hz, C-1*], 136.8 [2J (13C-119/117Sn) = 42 Hz, C-2*], 130.8 [ArC], 129.6 
[ArC], 129.3 [4J (13C-119/117Sn) = 13 Hz, C-4*], 128.6 [3J (13C-119/117Sn) = 65 Hz, C-3*], 124.9 [ArC], 118.4 
[ArC], 115.8 [ArC], 111.7 [ArC], 111.3 [ArC], 40.2 [C-14] ppm. 119Sn NMR (CDCl3); δSn: ‒108.7 ppm.  
 
2.3.6. Ph3SnL6 (6) 
  Ph3SnOH (0.68 g, 1.85 mmol); HL6 (0.50 g, 1.86 mmol). Recrystallized from acetonitrile to give a 
golden-yellow crystalline material in 71% yield. M.p.: 189-190 °C. Anal. calc. for C34H30N2O2Sn: C, 66.15; 
H, 4.90; N, 4.54 %.  Found. C, 66.26; H, 4.80; N, 4.68 %. IR (cm-1): 1632 ν(OCO)asym, 1370 ν(OCO)asym. 
Electronic absorption data (benzene)  λmax, nm; (ε [M‒1]): 452 (14,444). 1H-NMR (CDCl3): δH; 8.40 [s, 1H, 
H-15], 8.26 [d, 2H, H-3 & H-5], 7.94-7.92 [m, 6H, H-2*], 7.88 [d, 2H, H-9 & H-13], 7.53-7.50 [m, 9H, H-
3* & H4*], 7.29 [d, 2H, H-2 & H-6], 6.83 [d, 2H, H-10 & H-12], 3.16 [s, 6H, H-14] ppm. 13C-NMR 
(CDCl3): δC; 190.1 [C-1], 160.8 [C-15], 152.6 [C-7], 152.3 [C-11], 138.0 [1J (13C-119/117Sn) = 635/620 Hz, 
C-1*], 136.6 [2J (13C-119/117Sn) = 48 Hz, C-2*], 135.4 [ArC], 129.8 [4J (13C-119/117Sn) = 13 Hz, C-4*], 128.8 
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[ArC], 128.7 [ArC], 128.6 [3J (13C-119/117Sn) = 62 Hz, C-3*], 124.7 [ArC], 120.5 [ArC], 116.4 [ArC], 111.2 
[ArC], 110.6 [ArC], 39.8 [C-14] ppm. 119Sn NMR (CDCl3); δSn: ‒107.5 ppm.  
 
2.4. X-ray crystallography 
Single crystals suitable for an X-ray crystal structure determination were obtained from methanol 
(HL4 and 2) and acetonitrile (5) solutions of the respective compounds by slow evaporation of the solvent 
at room temperature. Intensity data for HL4, 2 and 5 were collected at room temperature on an Agilent 
Xcalibur Eos Gemini diffractometer equipped with a CCD area detector and graphite-monochromated Mo 
Kα radiation (λ = 0.71073 Å). Data reduction and empirical absorption correction, based on a multi-scan 
technique, was by standard methods [41]. The structures were solved by direct methods using SHELXS97 
[42] and refinement (anisotropic displacement parameters and C-bound hydrogen atoms in idealised 
positions) of each structure was carried out on F2 by using the full-matrix least-squares procedure 
incorporated in SHELXL2014/7 [43]. The hydroxyl-H atom in HL4 was located from a difference Fourier 
map and refined with the distance restraint O‒H = 0.82±0.01 Å.  A weighting scheme of the form w = 
1/[σ2(Fo2) + (aP)2 + bP] where P = (Fo2 + 2Fc2)/3 was introduced in each case. The final difference maps of 
HL4 and 2 exhibited no special features, but some evidence was found for disorder in the C41-phenyl ring 
of 5, as manifested by shorter than usual C–C bond lengths. However, multiple positions for the atoms 
comprising the C41-ring were not resolved in this room temperature determination. Crystal data and 
refinement details are given in Table 1. Molecular structure diagrams, showing the atom labelling schemes, 
were drawn with 50% displacement ellipsoids using ORTEP-3 for Windows [44] and the remaining 
crystallographic figures were drawn with DIAMOND [45]. Data manipulation and interpretation were 
accomplished using WinGX [44] and PLATON [46]. 
 
Insert Table 1 
2.5. Experimental protocol and cytotoxicity tests  
2.5.1. Stability assessment of triphenyltin(IV) compounds 1-6 in DMSO solution 
As mentioned in the introduction, the organotin(IV) compounds are dissolved in DMSO and 
diluted with test medium prior to in vitro testing and hence the stabilities of the triphenyltin(IV) compounds 
1-6 were assessed in DMSO prior to the cytotoxic studies. The absorbance spectra obtained from UV/Vis 
were monitored for 23 days (Fig. S1, ESI), with the unchanged basic pattern of the spectra of compounds 
indicating the compounds are stable in DMSO solution. 
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2.5.2. MTT assays 
MDA-MB 231, HeLa and HEK293 cell lines were used to determine cytotoxicity. The cell 
viability was checked by the MTT assay (colorimetric assay) based on the conversion of the yellow 
tetrazolium salt MTT to purple formazan crystals after reaction with mitochondrial dehydrogenase of 
metabolically active cells [47]. Stock solutions of pro-ligands, HLn and their compounds 1-6, and Ph3SnOH 
were prepared in DMSO and diluted with DMEM (a culture medium comprising 10% fetal bovine serum, 
supplemented with 20 mM L-glutamine, 100 units per mL penicillin and 100 µg mL-1 streptomycin) such 
that the final concentration of DMSO did not exceeded 0.1% v/v. The cell lines were maintained in 
complete DMEM at 37 °C under a humidified atmosphere of 5% CO2. Briefly, 1x104 HeLa, MDA-MB 231 
and HEK293 cells were seeded in three different 96 well cell culture plates. After 24 h, the culture medium 
was replaced by a fresh medium containing various concentrations of HLn and 1-6 and, incubated further 
for 24 h in 5% CO2 humidified atmosphere. The medium was then removed and 100 µL of fresh medium 
and 10 µL of 5 mg mL-1 MTT in phosphate buffered saline (PBS, pH 7.4) were added to each well and 
incubated further for 2 h. Finally, 100 µL of DMSO was added to dissolve the MTT formazan crystals 
followed by incubation for 30 min. Similarly; the MDA-MB 231 and HeLa cells were exposed to various 
concentrations of CDDP as the drug control. The absorbance of samples was measured at 570 nm with a 
plate reader. The percent cell inhibition was calculated with respect to control and IC50 (inhibitory 
concentration) values obtained were represented as mean ± SD for triplicates. 
 
2.5.2. ROS generation assay 
The intracellular ROS level was assessed using DCFH-DA. Briefly, MDA-MB 231, HeLa and 
HEK 293 cells were seeded in 6 well plates at a density of 4x105 cells per well for 24 h at 37 °C in a 
humidified atmosphere of 5% CO2. Then, HeLa cells were treated with complex 5 with concentrations of 
0.6, 0.8 and 1.0 µM (based on the IC50 value) for 24 h. Similarly, the MDAMB- 231 cells were then treated 
with the compounds 1 and 3 with concentrations of 0.5, 1.0 and 1.5 µM (based on the IC50 values) and 
HEK 293 cells were treated with compounds 1, 3 and 5 at the IC50 concentrations obtained against the 
cancer cells for 24 h at 37 °C maintaining the humidified atmosphere of 5% CO2. Then, the cells were 
washed with PBS and they were exposed in DCFH-DA dye (10 µM) for 30 min at 37 ºC. The cell samples 
were subjected to inverted fluorescence microscopy and DCF fluorescence was detected (λex = 485 nm; λem 
= 530 nm) and photographed. 
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2.5.3. Fluorescence staining of MDAMB-231 and HeLa cells for the detection of apoptotic cell death 
The MDAMB-231 and HeLa cells (2 x 105 ) were seeded in 6 well plates and kept for 24 h at 37 
°C in a humidified atmosphere of 5% CO2. Thereafter, cells were treated with the indicated concentrations 
of 1, 3 and 5 for 24 h. Subsequently, cells were washed with 1 x PBS and stained with Hoechst 33342 (10 
µg mL-1) and PI (15 µg mL-1) solutions and incubated at 37 °C for 20 min. Cells were then washed with 
PBS and images of nuclear morphology were recorded using an inverted fluorescent microscope in red and 
blue channels. 
 
2.5.4. Flow cytometry analysis of apoptosis  
The MDAMB-231 and HeLa cells (2 x105) were seeded in 12 well plates separately, as described 
above, and then treated with various concentrations of 1, 3 and 5, respectively, for 24 h and incubated in a 
CO2 incubator. After incubation, cells were washed with ice-cold PBS and harvested. The cells were 
centrifuged at 3000 rpm for 10 min. The cells were re-suspended in 100 µL of annexin binding buffer 
wherein 5 µL of annexin V Alexa fluor 488 conjugate and 1 µL of PI (100 µg mL-1) was added and 
incubated for 15 min at 37 °C in the dark. Finally, 400 µL of annexin binding buffer was added in each 
tube and the stained cells were analyzed by flow cytometry. 
 
2.5.5. Cell cycle analysis 
The MDAMB-231 and HeLa cells (4 x 105) were seeded in 6 well plates as described above, and 
then treated with indicated concentrations of 1, 3 and 5 for 24 h in DMEM with 10% FBS. Cells were then 
washed, trypsinized and fixed in ice-cold 70% ethanol and kept overnight at -20 °C. Then, the cells were 
washed twice in ice-cold PBS, and 500 µL of staining solution (0.1% (v/v) Triton X-100 solution, PI (1 mg 
mL-1) solution and RNase (10 mg mL-1 in PBS)) were added to each sample and incubated for 30 min at 
room temperature in the dark. After the staining procedure, the cell samples were assessed and the cell 
cycle distribution was analyzed using a FACS Aria II flow cytometer and analyzed using CELLQUEST 
software. 
 
     
3. Results and discussion 
3.1. Syntheses and spectroscopy 
In the present investigation, potential for influencing cytotoxicity was the motivation for 
combining the effects of triphenyltin esters, being located in ortho-, meta- and para- positions of 
molecules, with a diazenyl- or its isoelectronic imino group linking the aryl moieties (Fig. 1). Thus, six pro-
ligands containing diazenyl- and imino groups were selected, as these are likely to impart efficacious 
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biological activities [48-50]. The synthesis of pro-ligands, such as 2-{(E)-2-[4-
(dimethylamino)phenyl]diazenyl}benzoic acid and its meta- and para-derivatives (HL1-HL3) were achieved 
via a single-step procedure by reacting the appropriate carboxybenzenediazonium chloride with dimethyl 
aniline, using diazo-coupling reactions. On the other hand, 2-[(E)-{[4-
(dimethylamino)phenyl]methylidene}amino]benzoic acid and their derivatives (HL4-HL6) were synthesized 
by condensing the appropriate aniline with 4-(dimethylamino)benzaldehyde [39]. Crystalline triphenyltin 
esters (1-6) were synthesized by reacting equimolar amounts of Ph3SnOH with HLn, n = 1-6, in anhydrous 
toluene. Compounds were isolated as coloured crystalline solids in high yield. They are stable in air and 
soluble in common polar and non-polar organic solvents. Diagnostically significant spectral features were 
apparent. The IR spectra of compounds 1-6 each displayed a strong sharp band in the range 1615-1640 cm-1 
for the [ν(OCO)asym] while a band due to [ν(OCO)sym] was detected in the range 1332-1370 cm-1 (refer to 
the experimental section for specific values). The observed differences, i.e. Δ(νasym – νsym) in compounds 1-
6 are 254, 252, 259, 272, 297 and 262 cm-1, respectively, are indicative of an unidentate mode of 
coordination of carboxylate oxygen to the tin atom [51]. This inference is further supported by the 
correlation recently ascertained by Watkinson et al. [52] (Δ range from 107-565 cm-1 for unidentate and 45-
299 cm-1 for bidentate bridging mode). In the present study, the unidentate bonding modes of carboxylate 
ligands were subsequently confirmed from the results of single crystal X-ray diffractions data of 
representative compounds 2 and 5, in conjunction with a previously determined structure of 1 [40]. The 1H 
NMR integration values were entirely consistent with the formulation of the products and displayed 
expected resonances with no unusual features. The 13C{1H} NMR spectra displayed a carboxylate carbonyl 
carbon resonance at around 172 ppm for compounds 1 and 3 in CDCl3 while an upfield shift of this signal 
was noted for 2, appearing at 169 ppm in CDCl3/DMSO-d6 solvents. On the other hand, the carbonyl 
carbon resonances were detected at around 190 ppm in imino-analogues 4-6 and additionally a signal in the 
range 154-160 ppm was due to the imino carbon. Triphenyltin(IV) compounds 1-6 all share similar 
tetrahedral structural features in CDCl3 solution [53,54] as evidenced by 119Sn NMR which in each case 
featured a sharp singlet in the narrow range of ‒107.3 to ‒109.5 ppm. 
 
 
3.2. Description of the X-ray crystal structures 
 
Pro-ligand HL4 and two representative compounds Ph3SnL2 (2) and Ph3SnL5 (5) were analyzed by 
single crystal X-ray crystallography while the crystallographic structures of 3, 4 and 6 could not be solved 
owing to the poor quality of data sets. The molecular structure of HL4, Fig. 2, exhibits a small twist about 
the C2–N1 bond as seen in the C3–C2–N1–C8 torsion angle of 9.7(3)º leading to a dihedral angle of 
10.39(11)º between the aromatic rings. The conformation about the imine-C8‒N1 bond, 1.283(2) Å, is E; 
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other salient geometric parameters are collected in the figure caption. The carboxylic acid groups lies in the 
plane of aryl ring to which it is connected as seen in the O1‒C7‒C1‒C2 torsion angle of -6.0(3)º, a 
conformation which facilitates the formation of an intramolecular hydroxyl-O‒H…N(imine) hydrogen 
bond. In the molecular packing, supramolecular chains mediated by comparatively strong aryl-C‒
H…O(carbonyl) interactions are formed along [1 1 1], Fig. S2a, ESI. The chains are connected into 
supramolecular tubes by methyl-C–H…π(aryl) contacts, Fig. S2b, ESI and these pack with no specific 
interactions between them; the closest separations between aryl rings being > 4.8 Å, Fig. S2c, ESI. The 
molecular structure of the diazo analogue of HL4, namely 2-{(E)-2-[4-
(dimethylamino)phenyl]diazenyl}benzoic acid (HL1), has been determined previously by X-ray 
crystallography [55]. The structure presents essentially the same features as for HL4. The dihedral angle 
between the aryl rings is 12.86(11)º with the twist in the molecule occurring at the N‒C bond involving the 
4-dimethylamino-aryl ring; the N‒N‒C‒C torsion angle = 6.8(4)º. The intramolecular hydroxyl-O‒
H…N(imine) hydrogen bond persists. 
The molecular structure of the triphenyltin(IV) compound of the anion derived from HL2, i.e. 2, is 
illustrated in Fig. 3 and selected geometric parameters are included in the figure caption. The tin atom is 
tetrahedrally coordinated within a C3O donor set, implying a monodentate mode of coordination of the 
carboxylate ligand. This assignment is supported by the disparity of over 0.6 Å in the Sn–O1 and Sn…O2  
 
Insert Figs. 2 and 3 
 
separations, i.e. 2.0705(18) and 2.6529(17) Å. The C–O1, O2 bond lengths also differ significantly 
consistent with the presence of a carbonyl-O2 atom. Further, the distortions from a regular tetrahedral 
geometry are not great as seen in the range of the O1–Sn–C angles of 94.86(9) to 116.16(9)º and, in 
particular, of C–Sn–C angles, i.e. 108.80(10) to 115.41(10)º. A slightly reduced twist is found in the 
organic residue of the carboxylate ligand compared with that found in the free carboxylic acid [55] is noted 
and as seen in the C4–C3–N1–N2 torsion angle of -4.6(4)º with the twist occurring in the benzoate-C–
N(azo) bond; the carboxylate is co-planar with the ring it is connected to with the C6–C1–C7–O2 torsion 
angle being 179.8(2)º. The conformation about the diazo bond is E, as for the free ligand, and the N1=N2 
bond length is slightly reduced at 1.254(3) Å cf. 1.279(2) Å. The carbonyl-O2 atom does not form a 
significant intermolecular interaction in the molecular packing but it participates in a close intramolecular 
C26–H…O2 contact of 2.52 Å. The aryl rings of the carboxylate ligand are connected into a 
supramolecular chain along the a-axis via π…π interactions; the chain is reinforced by C–H…π 
interactions involving the tin-bound phenyl rings. Further C–H…π interactions involving tin-bound 
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phenyls results in a supramolecular layer in the ac-plane; a view of the unit cell contents is shown in Fig. 
S3, ESI.   
The structure of 5, illustrated in Fig. 4, presents much the same features as for 2. A disordered 
tetrahedral geometry is observed with the Sn…O2 separation being 2.723(2) Å cf. 2.068(2) Å for Sn–O1; 
the disparity in the C7–O1, O2 bond lengths persist. The ranges of O–Sn–C and C–Sn–C bond angles are 
93.17(9) to 114.81(10) and 110.66(11) to 115.44(11)º, respectively. The configuration about the imine C8–
N1 bond is E and the bond length of 1.244(5) Å is shorter than that in HL4. By contrast to the overall 
conformation in HL4, the carboxylate in 5 is highly twisted as manifested in the dihedral angle between the 
aryl rings of 51.83(17)º. There is also a twist between the carboxylate group and the ring to which it 
connected as seen in the C2–C1–C7–O2 torsion angle of 12.1(5)º. By contrast to 2, the carbonyl-O2 atom 
participates in a significant intermolecular interaction in the molecule packing of 5, forming a tin-bound-
phenyl-C–H…O contact, leading to a helical supramolecular chain along the b-axis. Chains are connected 
into a three-dimensional architecture by methyl- and tin-bound-phenyl-C–H…π(aryl) interactions where 
the accepting aryl rings are tin-bound-phenyl and both rings of the carboxylate ligand, see Fig. S4, ESI.   
 
Insert Fig. 4 
 
A crystal structure determination is available for 1 [40]. The weakly associated O2 atom in the 
distorted tetrahedral geometry is 2.827(3) Å from tin, i.e. further away than in 5, a result that might be 
correlated with steric pressure. The structure of the tri-n-butyl analogue is also known [56]. This is a 
polymeric compound as a result of bidentate, bridging carboxylate ligands leading to a trans-C3O2 donor 
set for tin and represents one of the two extremes for the overwhelming majority of triorganotin 
carboxylates, viz. polymeric, five coordinate on the one hand and monomeric, four coordinate on the other 
[57]. The structures of 1, 2 and 5 are examples of an intermediate geometry reflecting the close proximity 
of the carbonyl-O atom to tin. If the carboxylate ligands were considered bidentate, the geometry would be 
based on a cis-C3O2 donor set. While there is no precedent for other organotin structures with the meta-
isomeric carboxylate, one exists for the para-isomer. Here, a monodentate mode of coordination is found in 
its compound with {[(2-dimethylaminomethyl)phenyl](diphenyl)}tin(IV)-4-(4'-
dimethylaminophenylazo)benzoate [58]. In the same way, there is only one literature precedent for the 
carboxylate ligand in 5, namely in the unusual compound featuring three distinct, monodentate carboxylate 
ligands, (2-aminobenzoato)-[2-(4-dimethylaminobenzalidine)benzoato]-(2-
ammoniobenzoate)dimethyltin(IV) [59]. No precedents exist for organotin compounds with the meta- and 
para-isomeric carboxylate ligands.   
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3.2. Evaluation of in vitro cytotoxicity 
3.2.1. MTT assay 
The efficacy of triphenyltin(IV) compounds in suppressing tumor cells and advancing apoptosis has 
been well recognized [24-29]. Cytotoxic data for 1 and its pro-ligand HL1 on HCV29T (human bladder 
carcinoma) cell line has been reported briefly [40]. In the present investigation, the in vitro cytotoxic 
activities were evaluated using the MTT assay after incubation of 24 h.  IC50 values are given in Table 2 
while dose-dependent cytotoxic effects of triphenyltin(IV) compounds 1-6 on MDAMB-231 and HeLa 
are depicted in Fig. 5. Thus, it is clear that the compounds 1-6 exhibited considerable cytotoxicity in the 
sub-micromolar concentration range against the cell lines studied. 
 
Insert Fig. 5 
 
Among the test compounds included in the present investigation, 1 and 3 displayed significant 
inhibitory effects on the proliferation of the MDAMB-231 and HeLa cell lines in a dose-dependent 
manner and were found to be more potent than the clinically used drug, CDDP. The cytotoxicity of each 
of 1 and 3 was more pronounced against the MDAMB-231 cells at lower concentrations (IC50 = 1.19 and 
1.44 µM, respectively) while for HeLa cells the IC50 values were ≈ 2 µM; 2 did not show cytotoxicity up 
to 2 µM regardless of the cell lines explored. On the other hand, 5 exhibited dose-dependent toxicity for 
both MDAMB-231 and HeLa cell lines with IC50 values of 2.30 µM and 0.88 µM, respectively. However, 
4 and 6 exhibited toxicity at very high concentrations. The encouraging IC50 values for 1, 3 and 5 
prompted the determination of their cytotoxicity towards normal cells and indeed they did not induce 
cytotoxicity in the normal human kidney cells (HEK 293 cell line), up to a concentration of 3.2 µM with 
cell viability up to 60% (Fig. S5, ESI). It may be concluded that at low concentrations, 1 and 3 are potent 
cytotoxic agents for MDAMB-231 cells while 5 is potent towards HeLa cells and, therefore further 
experiments were conducted to ascertain the modes of cell death induced by 1, 3 and 5. 
 
3.2.2. Induction of ROS in MDAMB-231 and HeLa cells 
ROS are generally considered to be deleterious to cells, but ROS also have an important role in 
regulating signal transduction pathways and gene expressions. However, to effectively target cancer cells 
specific ROS-sensing signalling pathways that mediate the diverse stress-regulated cellular functions need 
to be identified [60,61]. Organotin(IV) compounds are known to induce apoptosis by increasing the 
intracellular ROS level [62]. The level of ROS induced in MDAMB-231 and HeLa cells by 1 and 3 at 
concentrations of 0.5, 1.0 and 1.5 µM, and 5 at concentrations of 0.6, 0.8 and 1.0 µM, respectively, were 
monitored using the probe DCFH-DA. DCFH-DA hydrolyzes to 2,7-dichlorodihydrofluorescein (DCFH) 
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in live cells, which in turn is oxidized to 2,7-dichlorofluorescein (DCF) in the presence of ROS, 
exhibiting a green fluorescence [63,64]. As compared to the control, a noteworthy increase in ROS level 
was induced by 1 and 3 in MDAMB-231 cell and 5 in HeLa cells (Fig. 6). The investigated compounds 
also displayed an elevated level of ROS generation in a dose-dependent manner in the respective cell lines 
with respect to the control, which could be one of the reasons that apoptosis is promoted in these cells. 
Further, generation of ROS was also measured in normal HEK 293 cells at their IC50 concentration 
obtained against cancer cell and it was observed that the compounds did not induce increased ROS 
production (Fig. S6, ESI), as compared to the cancer cells (Fig. 6) besides a few cells showing basal ROS 
induction.  
 
Insert Fig. 6 
 
3.2.3. Assessment of nuclear morphology during apoptosis by Hoechst 33342 and PI staining 
The apoptotic mode of cell death leads to distinct morphological and biochemical features, which 
are accompanied by nuclear shrinkage, cytoplasmic membrane blabbing, chromatin condensation, 
fragmentation of the nucleus, etc. [65,66]. To ascertain the intricacies of nuclear morphological changes 
during apoptosis, Hoechst 33342 and PI staining (DNA binding dyes) was employed with specified 
concentrations of compounds 1 and 3, and 5 on MDAMB-231 and HeLa cells, respectively, for 24 h. 
Selected images are shown in Fig. 7 wherein yellow, white and red arrows indicate viable, early apoptotic 
and late apoptotic (nuclei) cells, respectively. The live cells showed normal nuclei with blue chromatin 
whereas apoptotic cells showed nuclei with illuminated blue or pink chromatin that is mainly condensed 
or fragmented. The results also indicated that apoptotic cell death increases in a dose-dependent manner 
compared to the control. 
 
 
3.2.4. Apoptosis analysis by flow cytometry 
The annexin V- PI assays clearly indicated that 1, 3 and 5 induces apoptosis. At the IC50 
concentrations of 1 and 3, the increase in early apoptotic cell population was observed from 2.24% 
(control) to 9.49% and 18.18%, respectively, in MDAMB-231 cells. In the case of Hela cells, the increase 
in early apoptotic cell population was from 0.60% (control) to 9.49% at the IC50 concentration (0.8 µM) 
and to 10.45% at 1µM. The numbers of early apoptotic cells population were increased in a dose-
dependent manner while numbers of necrotic cell death is maximized at higher concentrations (Figs. 8a 
and 8b). 
 
Insert Figs. 8a and 8b 
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3.2.5. Cell cycle analysis 
Based on encouraging results described above, 1, 3 and 5 were further investigated in order to 
record changes on the cell cycle phase distribution on the basis of DNA content in MDAB-231 and HeLa 
cell lines after exposure for 24 h by flow cytometry analysis using PI staining [67]. Cells were treated 
with the concentrations close to the IC50 values determined for 1, 3 and 5. According to FACS histogram 
statistics (Fig. 9), the compounds induce shifts in the population of cells during cell cycle as compared to 
the control. Treatment of MDAB-231 cells with compound 1 (at 1.0 µM) induces an increase of the 
percentage of the apoptotic cells in the G2/M and sub-G1 phases while a decrease in the percentage at the 
G1 phase of the cell cycle was noted, compared to the control. On the other hand, when the same cells 
were treated with 3 at concentrations of 1.0 and 1.5 µM, no substantial change in the cell cycle phases 
were noted. However, the percentage of sub-G1 phase apoptotic cells increased from ca. 0.5% to 10% and 
49%, respectively, compared to the control. Similarly, treatment of HeLa cells with 5 at concentrations of 
0.6 and 0.8 µM induced an increase in the percentage of apoptotic cells (from ca. 23% to 34%) in the 
G2/M phase and a decrease (from ca. 60% to 43%) in the G1 phase while a marginal increase (from ca. 
1.4% to 5%) of apoptotic cells were noted at sub-G1 phase, with respect to control. The observed data 
suggests an arrest of the cell cycle in the G2/M phase. Thus, histogram statistics of FACS indicated the 
effect of 1, 3 and 5 in the cell cycle phases of MDAMB-231 and HeLa cells.  
 
Insert Fig. 9 
 
The in vitro cytotoxicities of the triphenyltin(IV) compounds were investigated using MDAMB-
231 and HeLa cell lines. Results confirmed that in comparison to triphenyltin(IV) compounds (1-6), free 
pro-ligands (HL1-HL6) showed no significant growth inhibition activities at a concentration greater than 
25 µM (Table 2), which signified that the chelation of the respective Ln- with Sn was essential for 
anticancer potential. When the cytotoxicities of diazo compounds 1-3, with variously substituted 
carboxylate on the phenyl ring, is compared with their isoelectronic imino analogues 4-6, no correlations 
could be ascertained. However, in the present study, ortho- and para- triphenyltin(IV) carboxylate 
(compounds 1 and 3) functionalization at the phenyl ring with a diazo group displayed the comparable 
activity towards MDAMB-231 cell lines whereas meta- derivatives with imino group (compound 5) 
demonstrated superior activity towards HeLa cells. However, they did not show cytotoxicity towards 
normal cell line, HEK 293. The active compounds (1, 3 and 5) elicit apoptotic cell death in MDAMB-231 
(1 and 3) and HeLa (5) cells, all in a dose-dependent fashion. Thus, it may be inferred that the apoptotic 
mechanisms induced by the triphenyltin(IV) compounds depends on cell type, specificity and 
concentrations, which is mainly prompted by apoptosis via ROS generation. 
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Conclusion 
In spite of several studies, the mechanisms of organotin(IV) induced apoptosis are still not fully 
understood and in this regard, small modular ligands with diazo- and its isoelectronic imino- scaffolds 
were used for the syntheses of triphenyltin(IV) carboxylates, where the carboxylate functionality was 
varied from ortho-, to meta- and para-positions. It was anticipated that this variation would significantly 
influence the nature of interaction with enzyme amino acid residues and hence, the activity of the 
compounds. In this pursuit, six triphenyltin(IV) esters, 1-6, have been characterized. Compounds 1 and 3 
functionalized with a diazo group displayed the comparable activity towards MDAMB-231 cell lines 
whereas compound 5, with an imino group, demonstrated superior activity towards HeLa cells. The 
results indicated that the location of triphenyltin ester in ortho-, meta- and para- positions of the ligand 
does exert a meaningful influence on the cytotoxicity. The tested compounds did not show any adverse 
cytotoxicity towards normal cell line, HEK 293, making them suitable candidates for drug development. 
The present study provides novel insight into the mechanism of cytotoxicity for new triphenyltin(IV) 
compounds. On the basis of the performances of 1-6, further studies were carried out using compounds 1, 
3 and 5. They were subjected to induce oxidative stress, which leads to apoptotic cell death as revealed 
from ROS measurement by DCFH-DA and Hoechst 33342/PI staining, respectively. Thus, compounds 
exert their antitumor effect by elevating intracellular ROS generation, independent of the cell line. 
Compound 5 was found to be the most potent compound, exhibiting very high cytotoxic activity (31-fold) 
compared to CDDP, importantly without affecting normal cells. The results suggest that 5 merits further 
investigation as a new potential therapeutic candidate for cancer treatment and may be a suitable 
candidate for modification in order to improve cytotoxic and dissolution properties. Further work in this 
area is underway. 
 
Abbreviations 
 
ROS reactive oxygen species 
IC50 compound concentrations that produce 50% of cell growth inhibition 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
DCFH-DA dichlorodihydrofluorescein diacetate 
PI propidium iodide 
CDDP cisplatin, cis-diammine-dichloroplatinum(II) 
FACS fluorescence-activated cell sorting 
DMEM Dulbecco’s modified eagle medium 
FBS fetal bovine serum 
ORTEP Oak Ridge thermal ellipsoid plot program (molecular modeling) 
PBS phosphate-buffered saline 
DCFH 2,7-dichlorodihydrofluorescein  
DCF 2,7-dichlorofluorescein  
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Appendix A. Supplementary data 
 
 
Crystallographic data for compounds HL4, 2 and 5 reported in this paper have been deposited with the 
Cambridge Crystallographic Data Centre (CCDC) as supplementary publication nos. 1489688-1489690. 
These data can be obtained free of charge via www.ccdc.cam.ac.uk/getstructures. 
The following information (Figs. S1-S6) are available as Supplementary Materials. Fig S1: Uv-Vis 
absorption spectra over time for triphenyltin(IV) compounds 1-6 in DMSO. Fig. S2: Molecular packing in 
HL4: (a) view of the supramolecular chain along [1 1 1] mediated by aryl-C-H…O(carbonyl) interactions, 
shown as orange dashed lines, (b) view of the supramolecular tube sustained by methyl-C–H…π(aryl) 
interactions shown as purple dashed lines and (c) view in projection down the c-axis of the unit cell 
contents.  Intermolecular contacts: C11–H11…O2i = 2.35 Å, C11…O2i = 3.212(3) Å with angle at H11 = 
153º.  C15–H15a…Cg(C1-C6)ii = 2.93 Å, C15… Cg(C1-C6)ii = 3.750(3) Å with angle at H15a = 143º.  
Symmetry operations: i, -½+x, -½+y, -½+z; ii, 1-x, 1-y, 1-z; Fig S3: View in projection down the a-axis of 
the unit cell contents of 2. Intermolecular contacts: π(C1-C6)…π(C8-C13)i, Cg…Cg = 3.6664(15) Å for 
dihedral angle 7.21(13)º, shown as blue dashed lines.  C24–H24…Cg(C31-C36)ii = 2.88 Å, 
C24…Cg(C31-C36)ii = 3.793(4) Å with angle at H24 = 167º.  C35–H35…Cg(C41-C46)i = 2.88 Å, 
C35…Cg(C41-C46)i = 3.623(4) Å with angle at H35 = 137º.  C–H…π contacts are shown as purple 
dashed lines.  Symmetry operations: i, 1+x, y, z; ii, x, ½-y, -½+z; Fig. S4: View in projection down the a-
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axis of the unit cell contents of 5.  Intermolecular contacts: C24–H24...O2i = 2.57 Å, C24...O2i = 3.307(5) 
Å with angle at H24 = 137º, shown as orange dashed lines.  C15–H15B…Cg(C1-C6)ii = 2.91 Å, 
C15…Cg(C1-C6)ii = 3.781(6) Å with angle at H15B = 151º.  C44–H44…Cg(C9-C14)iii = 2.92 Å, 
C44…Cg(C9-C14)iii = 3.546(4) Å with angle at H44 = 125º.  C45–H45…Cg(C31-C36)iv = 2.99 Å, 
C45…Cg(C31-C36)iv = 3.670(5) Å with angle at H45 = 132º.  C–H…π contacts are shown as purple 
dashed lines.  Symmetry operations: i, 1-x, -½+y, 1½-z; ii, 1+x, y, z; iii, -1+x, ½-y, -½+z; iv, -x, ½+y, 1½-
z; Fig. S5: Dose dependent cytotoxic effects (a) Bar and (b) Graphical representations of compounds 1, 3 
and 5 on HEK 293 cells by MTT assay after incubation with various concentrations of compounds for 24 
h. Bars represent ± SEM (n = 3). Fig. S6: Generations of ROS induced by 1 and 3 in MDAMB-231 and 5 
in Hela cells viewed through fluorescence microscope, when treated with IC50 concentrations of the 
respective compounds (see Table 2). 
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Fig. 1 Generic structures with numbering protocol of pro-ligands HLn (n = 1-6) and tin phenyl 
moiety.  
 
 
 
Fig. 2 Perspective view of the molecular structure of HL4. Selected geometric parameters: 
C7‒O1 1.311(3), C7‒O2 1.214(3), C8‒N1 1.283(2) Å, O1‒C7‒O2 121.4(2), C2‒N1‒C8 
123.31(18), N1‒C8‒C9 123.98(19)º.  Intramolecular hydrogen bond: O1‒H1o…N = 1.71(2) 
Å, O1…N1 = 2.504(2) Å with an angle of 157(3)º subtended at H1o. 
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Fig. 3 Perspective view of the molecular structure of 2. Selected geometric parameters: Sn‒
O1 2.0705(18), C7‒O1 1.307(3), C7‒O2 1.234(3), N1‒N2 1.254(3) Å. 
 
 
 
Fig. 4 Perspective view of the molecular structure of 5. Selected geometric parameters: Sn‒
O1 2.068(2), C7‒O1 1.311(3), C7‒O2 1.224(3), C8‒N1 1.244(5) Å. 
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Fig. 5. Dose dependent cytotoxic effects of compounds 1-6 on (a) MDAMB-231 and (b) HeLa 
cells by MTT assay after incubation with various concentrations of compounds for 24 h. Bars 
represent ± SEM (n = 3). Statistical analysis has been done by one way ANOVA followed by 
Tukey test where * denotes significant difference (P <0.05) as compared to control. 
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Fig. 6 Dose-dependent generations of ROS when treated with IC50 concentrations of the 
respective compounds induced by (a) 1 and 3 in MDAMB-231 and (b) 5 in Hela cells detected 
by measuring the fluorescence intensity using DCFH-DA viewed through fluorescence 
microscope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control' Control'
Compound 5'(0.6'µM)' Compound 5'(0.8'µM)' Compound 5'(1.0'µM)'
Compound 5'(0.6'µM)'
Compound 5'(0.8'µM)' Compound 5'(1.0'µM)'
(b) 
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Fig. 7 Fluorescence microscope images showing morphological (nuclear) changes in MDAMB-231 and 
HeLa cells upon treatment with specified concentrations of compounds (1 and 3) and (5), respectively, by 
dual staining with Hoechst 33342 and PI for 24 h. Yellow arrows represents live cell nuclei, white arrows 
show bright blue condensed apoptotic nuclei whereas red arrows show pink fragment apoptotic nuclei. 
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Fig. 8 Assessment of apoptosis by annexin V alexa fluor 488 and propidium iodide (PI) dual 
staining in MDAMB-231 and HeLa cells populations (%) after 24 h treatment (a) with 1.0 µM 
concentration (IC50 value) of compounds 1 and 3 for MDAMB-231 (b) with 0.6 µM (< IC50 
value), 0.8 µM (IC50  value) and 1.0 µM (> IC50 value) concentrations of compound 5 for HeLa 
cells. The upper left quadrant shows necrotic cells (PI +ve/ annexin V -ve), upper right quadrant 
shows late apoptotic cells (PI +ve/ Annexin V +ve), lower left quadrant shows live cells (PI –ve/ 
Annexin V –ve) and lower right quadrant shows early apoptotic cells (PI –ve/ Annexin V +ve). 
Percentage of cells in four quadrants were calculated from three individual experiments.  
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  Control 
       1 (0.5 µM)        1 (1.0 µM)       1 (1.5 µM) 
       3 (0.5 µM)       3 (1.0 µM)        3 (1.5 µM) 
  Control   5 (0.6 µM)   5 (0.8 µM) 
(b) 
Fig. 7 Distributions of cell cycle phases studied through FACS analysis of PI stained  (a) MDAMB-231    
and (b) HeLa cells, after 24 h of exposure to concentrations of compounds 1, 3 and 5. The data 
indicated in the histogram refers to the percentage of cells in each phase of the cell cycle. Statistical 
analysis has been done by  one way ANOVA followed by Tukey test where * denotes significant 
difference (P <0.05) as compared  to control  
 
 
(a) 
(b) 
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Fig. 9 Distributions of cell cycle phases studied through FACS analysis of PI stained (a) 
MDAMB-231 and (b) HeLa cells, after 24 h of exposure to concentrations of compounds 1, 3 
and 5. The data indicated in the histogram refers to the percentage of cells in each phase of the 
cell cycle. Statistical analysis has been performed by one way ANOVA followed by Tukey test 
where * denotes significant difference (P <0.05) as compared to control. 
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Table 1  
Crystal data and refinement details for pro-ligand HL4 and triphenyltin(IV) compounds 2 and 5 
Compound HL4 2 5 
Formula C16H16N2O2 C33H29N3O2Sn C34H30N2O2Sn 
Formula weight 268.31 618.28 617.29 
Crystal colour yellow orange-red dark-orange 
Crystal size/mm3 0.12x0.16x0.22 0.12x0.15x0.24 0.12x0.24x0.32 
Crystal system monoclinic monoclinic monoclinic 
Space group I2/a P21/c P21/c 
a/Å 15.3620(8) 7.8101(3) 10.4484(4) 
b/Å 13.0274(5) 19.1380(9) 14.6258(6) 
c/Å 14.4686(7) 19.5298(8) 19.6944(7) 
β/° 105.179(6) 97.547(4) 100.490(3) 
V/Å3 2794.5(2) 2893.8(2) 2959.3(2) 
Z 8 4 4 
Dc/g cm-3 1.275 1.419 1.385 
F(000) 1136 1256 1256 
µ(MoKα)/mm-1 0.085 0.917 0.895 
Measured data 5877 13908 12838 
θ range/° 3.1 – 26.5 3.3 – 26.5 3.0 – 26.5 
Unique data 2883 5973 6102 
Observed data (I ≥ 2.0σ(I)) 1824 4784 4642 
No. parameters 186 354 354 
R, obs. data; all data 0.056; 0.092 0.032; 0.047 0.036; 0.056 
a; b in weighting scheme 0.059; 1.198 0.031; 0.366 0.032; 0 
Rw, obs. data; all data 0.130; 0.155 0.067; 0.073 0.073; 0.081 
GoF 1.03 1.03 1.06 
Range of residual electron 
density peaks/eÅ-3 -0.19 – 0.24 -0.26 – 0.30 -0.32 – 0.44 
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Table 2  
IC50 values (µM) for free pro-ligands and triphenyltin(IV) compounds 
1-6, Ph3SnOH and CDDP after 24 h exposure in cancer cell lines 
(MDAMB-231 and HeLa) and  normal cells HEK 293  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aStandard error. 
bND = Not done. 
 
 
 
 
 
 
 
Test compounds                        IC50 values (µM) ± SEa 
 MDAMB-231 cells HeLa cells HEK 293 cells 
HL1 > 25 > 25  
HL2 > 25 > 25  
HL3 > 25 > 25  
HL4 > 25 > 25  
HL5 > 25 > 25  
HL6 > 25 > 25  
Ph3SnL1   (1) 1.19 ± 0.16 2.23 ± 0.08 2.68 ± 0.07 
Ph3SnL2    (2) 3.83 ± 0.15 2.5 ± 0.19 b 
Ph3SnL3    (3) 1.44 ± 0.03 1.78 ± 0.12 3.28 ± 0.25 
Ph3SnL4    (4) 3.76 ± 0.06 6.18 ± 0.03 b 
Ph3SnL5    (5) 2.30 ± 0.02 0.88 ± 0.0003 3.91 ± 0.08 
Ph3SnL6    (6) 2.45 ± 0.02 3.99 ± 0.16 b 
CDDP 5.62 ± 0.30 23.63± 0.20 b 
Ph3SnOH > 15 > 15  
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Legends to the figures 
 
Fig. 1 Generic structures with numbering protocol of pro-ligands HLn (n = 1-6) and tin phenyl moiety  
 
Fig. 2 Perspective view of the molecular structure of HL4. Selected geometric parameters: C7‒O1 
1.311(3), C7‒O2 1.214(3), C8‒N1 1.283(2) Å, O1‒C7‒O2 121.4(2), C2‒N1‒C8 123.31(18), N1‒C8‒
C9 123.98(19)º.  Intramolecular hydrogen bond: O1‒H1o…N = 1.71(2) Å, O1…N1 = 2.504(2) Å with 
an angle of 157(3)º subtended at H1o. 
 
Fig. 3 Perspective view of the molecular structure of 2. Selected geometric parameters: Sn‒O1 
2.0705(18), C7‒O1 1.307(3), C7‒O2 1.234(3), N1‒N2 1.254(3) Å. 
 
Fig. 4 Perspective view of the molecular structure of 5. Selected geometric parameters: Sn‒O1 
2.068(2), C7‒O1 1.311(3), C7‒O2 1.224(3), C8‒N1 1.244(5) Å. 
 
Fig. 5 Dose dependent cytotoxic effects of compounds 1-6 on (a) MDAMB-231 and (b) HeLa cells by 
MTT assay after incubation with various concentrations of compounds for 24 h. Bars represent ± SEM (n 
= 3). Statistical analysis has been done by one way ANOVA followed by Tukey test where * denotes 
significant difference (P <0.05) as compared to control. 
 
Fig. 6 Dose-dependent generations of ROS when treated with IC50 concentrations of the respective 
compounds induced by (a) 1 and 3 in MDAMB-231 and (b) 5 in Hela cells detected by measuring the 
fluorescence intensity using DCFH-DA viewed through fluorescence microscope. 
 
Fig. 7 Fluorescence microscope images showing morphological (nuclear) changes in MDAMB-231 and 
HeLa cells upon treatment with specified concentrations of compounds (1 and 3) and (5), respectively, by 
dual staining with Hoechst 33342 and PI for 24 h. Yellow arrows represents live cell nuclei, white arrows 
show bright blue condensed apoptotic nuclei whereas red arrows show pink fragment apoptotic nuclei. 
 
Fig. 8 Assessment of apoptosis by annexin V alexa fluor 488 and propidium iodide (PI) dual staining in 
MDAMB-231 and HeLa cells populations (%) after 24 h treatment (a) with 1.0 µM concentration (IC50 
value) of compounds 1 and 3 for MDAMB-231 (b) with 0.6 µM (< IC50 value), 0.8 µM (IC50  value) and 
1.0 µM (> IC50 value) concentrations of compound 5 for HeLa cells. The upper left quadrant shows 
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necrotic cells (PI +ve/ annexin V -ve), upper right quadrant shows late apoptotic cells (PI +ve/ Annexin V 
+ve), lower left quadrant shows live cells (PI –ve/ Annexin V –ve) and lower right quadrant shows early 
apoptotic cells (PI –ve/ Annexin V +ve). Percentage of cells in four quadrants were calculated from three 
individual experiments.  
 
Fig. 9 Distributions of cell cycle phases studied through FACS analysis of PI stained (a) MDAMB-231 
and (b) HeLa cells, after 24 h of exposure to concentrations of compounds 1, 3 and 5. The data indicated 
in the histogram refers to the percentage of cells in each phase of the cell cycle. Statistical analysis has 
been performed by one way ANOVA followed by Tukey test where * denotes significant difference (P 
<0.05) as compared to control. 
 
 
